30896-57-2

Basic information

• Product Name: 4-HYDROXYALPRAZOLAM
• Synonyms: 4-Hydroxy Alprazolam Methanoate
• CAS NO: 30896-57-2
• Molecular Formula: C₁₇H₁₃ClN₄O
• Molecular Weight: 324.77
• Product Categories: Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 30896-57-2.mol
• Article Data: 3

Chemical Properties

• Melting Point: 160-1620C
• Boiling Point: 559.2°Cat760mmHg
• Flash Point: 292°C
• Appearance: /
• Density: 1.45g/cm³
• Vapor Pressure: 2.42E-13mmHg at 25°C
• Refractive Index: 1.731
• Storage Temp.: Controlled Substance, -20?C Freezer
• PKA: 11.59±0.40(Predicted)
• CAS DataBase Reference: 4-HYDROXYALPRAZOLAM(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXYALPRAZOLAM(30896-57-2)
• EPA Substance Registry System: 4-HYDROXYALPRAZOLAM(30896-57-2)

Safety Data

• Hazardous Substances Data: 30896-57-2(Hazardous Substances Data)

Usage

Description

4-Hydroxyalprazolam, a metabolite of alprazolam, is a benzodiazepine derivative with anxiolytic and sedative properties. It is produced by the actions of cytochrome P450 (CYP) isoforms CYP3A4 and CYP3A5 and can be detected in serum or, in a glucuronidated form, in urine. 4-Hydroxyalprazolam is a white solid and is considered a controlled substance.

Uses

Used in Pharmaceutical Industry:
4-Hydroxyalprazolam is used as a metabolite in the pharmaceutical industry for its anxiolytic and sedative effects. It is derived from alprazolam, a benzodiazepine, and is involved in the metabolic pathway of the drug, potentially contributing to its overall therapeutic effects.
Used in Research and Development:
4-Hydroxyalprazolam is used as a research compound for studying the metabolism and pharmacokinetics of alprazolam. Understanding the role of this metabolite can help in the development of new drugs with improved efficacy and safety profiles.
Used in Toxicology and Drug Testing:
4-Hydroxyalprazolam is used as a biomarker in toxicology and drug testing to detect the presence of alprazolam or its metabolites in biological samples. This can be useful in monitoring drug use, assessing compliance with prescribed medications, or investigating cases of drug abuse or overdose.

InChI:InChI=1/C17H13ClN4O/c1-10-20-21-16-17(23)19-15(11-5-3-2-4-6-11)13-9-12(18)7-8-14(13)22(10)16/h2-9,17,23H,1H3

Upstream product

• 30896-67-4 8-chloro-4-hydroxy-1-methyl-6-phenyl-4H-s-triazolo<4,3-a><1,4>benzodiazepine acetate 
• 36916-20-8 4-(2-benzoyl-4-chlorophenyl)-5-methyl-4H-1,2,4-triazole-3-carboxaldehyde 
• 28981-97-7 alprazolam 
• 30896-65-2 8-chloro-1-methyl-6-phenyl-4H-s-triazolo<4,3-a><1,4>benzodiazepine 5-oxide 
• 36916-14-0 10-chloro-6-methyl-11b-phenyl-3H,11bH-oxazirino<3,2-d>-s-triazolo<4,3-a><1,4>benzodiazepine 
• 16416-12-9 7-chloro-2-methoxy-5-phenyl-3H-1,4-benzodiazepine 4-oxide 

Downstream Products

• 62659-63-6 4-fluoro-8-chloro-1-methyl-6-phenyl-4H-5-triazolo<4.3.a>-<1,4>benzodiazepine 
• 36916-15-1 8-chloro-5,6-dihydro-1-methyl-6-phenyl-4H-s-triazolo<4,3-a><1,4>benzodiazepin-4-one 
• 30896-67-4 8-chloro-4-hydroxy-1-methyl-6-phenyl-4H-s-triazolo<4,3-a><1,4>benzodiazepine acetate 

Relevant articles and documents

Prediction of metabolic clearance using fresh human hepatocytes: Comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines

1. Predictions of in vivo intrinsic clearance from cryopreserved human hepatocytes may be systematically low. In the current study, the metabolite kinetics of a series of CYP3A4 substrates (benzodiazepines) in fresh human hepatocytes from five donors, via a major UK supplier, were investigated and compared with those previously reported (by the authors' laboratory) for cryopreserved human hepatocytes and hepatic microsomes. 2. A high incidence of autoactivation (up to tenfold) and heteroactivation (by testosterone, up to 14-fold) among the major pathways was observed. CYP capacity (Vmax) was marginally lower and 'affinity' constants (KM, S50) were marginally greater compared with cryopreserved hepatocytes. 3. Average intrinsic clearance (based on maximal clearance, CLmax) was sevenfold lower than in cryopreserved hepatocytes (reflecting sensitivity of intrinsic clearance estimation in vitro to mechanistic parameter values, particularly those involving atypical kinetics), but scaled intrinsic clearances for fresh (and cryopreserved) hepatocytes were within the range previously determined in hepatic microsomes. 4. There was no evidence from this series of studies that fresh hepatocytes provide quantitatively improved estimates of intrinsic clearance over cryopreserved hepatocytes.

Preparation of triazolo benzodiazepines and novel compounds

Novel preparations of triazolobenzodiazepines are disclosed. Novel 6-pyridyl-4H-triazolo[4,3-a]-1,4-benzodiazepines and novel intermediates are also disclosed which are useful as anti-convulsants, muscle relaxants and sedative agents.